Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

2006 • 1,874 citations

Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

2005 • 1,212 citations

Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

2006 • 1,146 citations

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 • 875 citations

Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma

2004 • 582 citations

Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group

2000 • 536 citations

Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data

2004 • 514 citations

Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer

2002 • 483 citations

Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

2002 • 429 citations

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1993 • 360 citations

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

2006 • 285 citations

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1999 • 279 citations

Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803

2004 • 275 citations

Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

1999 • 272 citations

Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group

2007 • 245 citations

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

2007 • 245 citations

Design and analysis of non‐inferiority mortality trials in oncology

2002 • 236 citations

Points to consider on switching between superiority and non‐inferiority

2001 • 181 citations

[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].

1994 • 171 citations

CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma

2002 • 166 citations

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

2004 • 160 citations

A useful testing strategy in phase iii trials: combined test of superiority and test of equivalence

1995 • 140 citations

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.

1997 • 139 citations

A Systematic Overview of Chemotherapy Effects in Gastric Cancer

2001 • 132 citations

Incidence and mortality from stomach cancer in Japan, Slovenia and the USA

2001 • 122 citations

Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial

2006 • 108 citations

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

2005 • 98 citations

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

2003 • 90 citations

Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie

2007 • 69 citations

A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma

2005 • 59 citations

Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy.

1994 • 42 citations

Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer

2001 • 26 citations

A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

2005 • 19 citations

3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study

2007 • 4 citations

Cited By (0)

No citing papers found in database